Todd Bazemore Kala Pharmaceuticals, Inc. (KALA) insider trading activity

Todd Bazemore is of Kala Pharmaceuticals, Inc.. Currently has a direct ownership of 35,932 shares of KALA, which is worth approximately $25,511. The most recent transaction as insider was on Oct 22, 2025, when has been sold 47,768 shares (Common Stock) at a price of $0.83 per share, resulting in proceeds of $39,647. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 35.9K

57.07% 3M change

56.73% 12M change

Total Value Held $25,511

Todd Bazemore Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Oct 22 2025	SELL Open market or private sale	$39,647 $0.83 p/Share	47,768 Reduced 57.07%	35,932 Common Stock
Jun 24 2025	SELL Open market or private sale	$16,272 $4.01 p/Share	4,058 Reduced 4.62%	83,699 Common Stock
Jun 03 2025	SELL Open market or private sale	$12,678 $3.74 p/Share	3,390 Reduced 3.72%	87,757 Common Stock
Jan 06 2025	SELL Open market or private sale	$15,206 $7.63 p/Share	1,993 Reduced 2.14%	91,147 Common Stock
Jan 06 2025	BUY Grant, award, or other acquisition	-	10,100 Added 9.78%	93,140 Common Stock
Jun 26 2024	SELL Open market or private sale	$22,101 $4.75 p/Share	4,653 Reduced 5.31%	83,040 Common Stock
May 31 2024	SELL Open market or private sale	$12,746 $6.09 p/Share	2,093 Reduced 2.33%	87,693 Common Stock
Jan 04 2024	SELL Open market or private sale	$9,469 $6.74 p/Share	1,405 Reduced 1.54%	89,786 Common Stock
Jan 04 2024	BUY Grant, award, or other acquisition	-	6,500 Added 6.65%	91,191 Common Stock
Jun 22 2023	BUY Grant, award, or other acquisition	-	48,698 Added 36.51%	84,691 Common Stock
May 31 2023	BUY Grant, award, or other acquisition	-	21,158 Added 37.02%	35,993 Common Stock
Jan 04 2023	SELL Open market or private sale	$1,769 $28.54 p/Share	62 Reduced 0.42%	14,835 Common Stock
Jan 04 2023	BUY Grant, award, or other acquisition	-	12,800 Added 46.21%	14,897 Common Stock
Oct 26 2022	SELL Open market or private sale	$1,393 $6.51 p/Share	214 Reduced 9.26%	2,097 Common Stock
Jun 27 2022	SELL Open market or private sale	$1,144 $0.37 p/Share	3,092 Reduced 2.61%	115,499 Common Stock
Jan 04 2022	SELL Open market or private sale	$4,490 $1.3 p/Share	3,454 Reduced 2.83%	118,591 Common Stock
Oct 26 2021	SELL Open market or private sale	$22,579 $1.8 p/Share	12,544 Reduced 9.32%	122,045 Common Stock
Jun 28 2021	SELL Open market or private sale	$16,796 $5.77 p/Share	2,911 Reduced 2.12%	134,589 Common Stock
Jan 04 2021	BUY Grant, award, or other acquisition	-	27,500 Added 16.67%	137,500 Common Stock
Oct 26 2020	BUY Grant, award, or other acquisition	-	81,000 Added 42.41%	110,000 Common Stock

Also insider at

PULM

Pulmatrix, Inc. Healthcare

Director

Todd Bazemore

Watertown, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KALA shares.

Notify only if

Value

Insider Trading

Get notified when an Kala Pharmaceuticals, Inc. insider buys or sells KALA shares.

Notify only if

Operation

Value

Type

News

Receive news related to Kala Pharmaceuticals, Inc.

Track Activities on KALA

Account